Biotechnology firm RadioMedix and global nuclear medicine firm Curium have received U.S. Food and Drug Administration (FDA) clearance for their Detectnet PET diagnostic radiopharmaceutical copper-64 (Cu-64) DOTATATE.
Detectnet is indicated for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients, according to the vendors. Curium said it plans to immediately launch Detectnet. Doses will be available through various nuclear pharmacies or directly from Curium.
